Ascletis Pharma Inc.
Ascletis Pharma Inc. (ASCLF) Financial Performance & Income Statement Overview
View comprehensive annual and quarterly summaries for Ascletis Pharma Inc. (ASCLF), featuring income statements, balance sheets, and cash flow data.
Ascletis Pharma Inc. (ASCLF) Income Statement & Financial Overview
View the income breakdown for Ascletis Pharma Inc. ASCLF across both annual and quarterly reports.
Metric | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
---|---|---|---|---|
Revenue | $641500.00 | $641500.00 | $0.00 | $0.00 |
Cost of Revenue | $274000.00 | $274000.00 | $0.00 | $0.00 |
Gross Profit | $367500.00 | $367500.00 | $0.00 | $0.00 |
Gross Profit Ratio | $0.57 | $0.57 | $0.00 | $0.00 |
R&D Expenses | $85.006M | $85.006M | $66.19M | $66.19M |
SG&A Expenses | $30.19M | $30.19M | $20.68M | $20.68M |
Operating Expenses | $115.20M | $115.20M | $86.87M | $86.87M |
Total Costs & Expenses | $115.47M | $115.47M | $86.87M | $86.87M |
Interest Income | $0.00 | $0.00 | $0.00 | $0.00 |
Interest Expense | $0.00 | $0.00 | $0.00 | $0.00 |
Depreciation & Amortization | $3.51M | $4.01M | $4.01M | $4.01M |
EBITDA | -$111.83M | -$111.34M | -$82.96M | -$82.96M |
EBITDA Ratio | -$174.33 | -$173.55 | $0.00 | $0.00 |
Operating Income | -$114.83M | -$114.83M | -$86.87M | -$86.87M |
Operating Income Ratio | -$179.006 | -$179.006 | $0.00 | $0.00 |
Other Income/Expenses (Net) | $29.52M | $29.52M | $21.71M | $21.71M |
Income Before Tax | -$85.31M | -$85.31M | -$65.16M | -$65.16M |
Income Before Tax Ratio | -$132.98 | -$132.98 | $0.00 | $0.00 |
Income Tax Expense | $0.00 | $0.00 | $0.00 | -$99500.00 |
Net Income | -$85.31M | -$85.31M | -$65.16M | -$65.16M |
Net Income Ratio | -$132.98 | -$132.98 | $0.00 | $0.00 |
EPS | -$0.09 | -$0.09 | -$0.06 | -$0.06 |
Diluted EPS | -$0.09 | -$0.09 | -$0.06 | -$0.06 |
Weighted Avg Shares Outstanding | $986.77M | $986.77M | $1.02B | $1.02B |
Weighted Avg Shares Outstanding (Diluted) | $986.77M | $986.77M | $1.02B | $1.02B |
Over the last four quarters, Ascletis Pharma Inc. achieved steady financial progress, growing revenue from $0.00 in Q1 2024 to $641500.00 in Q4 2024. Gross profit stayed firm with margins at 57% in Q4 2024 versus N/A in Q1 2024. Operating income totaled -$114.83M in Q4 2024, maintaining a -17901% margin over recent quarters. Despite shifts in R&D and SG&A costs, EBITDA stayed strong at -$111.83M. Net income rose to -$85.31M, with EPS at -$0.09. Disciplined expense strategies and efficient operations ensured sustained profitability and long-term financial stability.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan